Finerenone is a drug that blocks excessive activity of the hormone aldosterone and protects the kidneys from damage in chronic kidney disease (CKD) associated with type 1 diabetes (T1D).[1] The phase 3 FINE-ONE clinical trial demonstrated that finerenone significantly reduced the urinary albumin-to-creatinine ratio (UACR), a measure of kidney damage, compared to placebo.[1][7] This 25% decrease in UACR indicates a lower risk of renal disease progression, renal failure, and cardiovascular events.[1][7] Finerenone was well tolerated, with no new safety issues and few serious adverse events.[1] The drug is already approved for the treatment of CKD in type 2 diabetes, and Bayer plans to submit data to expand the indication to include T1D.[1] The FINE-ONE study was global and met its primary objective of reducing UACR.[1]